ナジフロキサシン
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2013/09/12 00:08:45」(JST)
[Wiki en表示]
Nadifloxacin
|
Systematic (IUPAC) name |
(RS)-9-Fluoro-8-(4-hydroxy-piperidin-1-yl)-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylic acid |
Clinical data |
AHFS/Drugs.com |
International Drug Names |
Pregnancy cat. |
? |
Legal status |
? |
Routes |
topical (epicutaneous) |
Identifiers |
CAS number |
124858-35-1 Y |
ATC code |
None |
PubChem |
CID 4410 |
UNII |
6CL9Y5YZEQ Y |
Chemical data |
Formula |
C19H21FN2O4 |
Mol. mass |
360.379 g/mol |
Y (what is this?) (verify)
|
Nadifloxacin (INN, brand names Acuatim, Nadiflox, Nadoxin, Nadixa, activon) is a topical fluoroquinolone antibiotic for the treatment of acne vulgaris.[1] It is also used to treat bacterial skin infections.
Contents
- 1 Pharmacology
- 1.1 Antibacterial spectrum
- 1.2 Mechanism of action
- 1.3 Pharmacokinetics
- 2 See also
- 3 References
Pharmacology[edit source | edit]
Antibacterial spectrum[edit source | edit]
In vitro studies of nadifloxacin showed potent and broad-spectrum antibacterial activity against aerobic Gram-positive, Gram-negative and anaerobic bacteria, including Propionibacterium acnes and Staphylococcus epidermidis. Nadifloxacin showed potent antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA), which was similar to potency against methicillin-sensitive Staphylococcus aureus (MSSA). The drug was also active against new quinolone-resistant MRSA. Nadifloxacin does not show cross-resistance with other new quinolones.
In patients with skin lesions, topical application of nadifloxacin can result in plasma concentrations of 1 to 3 ng/ml. Consequently, it has been argued that it should not be used to treat relatively harmless diseases like acne vulgaris, risking the development of quinolone resistances.[2]
Mechanism of action[edit source | edit]
Nadifloxacin inhibits the enzyme DNA gyrase that is involved in bacterial DNA synthesis and replication, thus inhibiting the bacterial multiplication.
Pharmacokinetics[edit source | edit]
Following a single topical application of 10 g nadifloxacin 1% cream to normal human back skin, the highest plasma concentration was determined to be 107 ng/mL with an elimination half-life of 19.4 hours. Approximately 0.09% of the administered dose was excreted in the urine over 48 hours post- dosing. The plasma concentration reached a steady state on Day 5 of repeated administration study when nadifloxacin 1% cream was applied at 5 gm twice daily to normal healthy individuals for a period of 7 days. The plasma concentration reached a peak of 4.1 ng/ml at 8 hours post-final dosing with an elimination half-life of 23.2 hours. The urinary excretion rate reached 0.16% on Day 7.
See also[edit source | edit]
- Adverse effects of fluoroquinolones
References[edit source | edit]
- ^ Murata K, Tokura Y (March 2007). "[Anti-microbial therapies for acne vulgaris: anti-inflammatory actions of anti-microbial drugs and their effectiveness]". J. UOEH (in Japanese) 29 (1): 63–71. PMID 17380730.
- ^ Steinhilber; Schubert-Zsilavecz, Roth (2004). Medizinische Chemie: Targets und Arzneistoffe. WVG Stuttgart.
Antibiotics and chemotherapeutics for dermatological use (D06)
|
|
Antibiotics |
Tetracycline and derivatives
|
- Demeclocycline
- Chlortetracycline
- Oxytetracycline
- Tetracycline
|
|
Others
|
- Amphenicol: Chloramphenicol
- Aminoglycosides: Neomycin
- Gentamicin
- Amikacin
- Streptogramin: Virginiamycin
- other: Fusidic acid
- Bacitracin
- Tyrothricin
- Mupirocin
|
|
|
Chemotherapeutics |
Sulfonamides
|
- Silver sulfadiazine
- Sulfathiazole
- Mafenide
- Sulfamethizole
- Sulfanilamide
- Sulfamerazine
|
|
Antivirals
|
- Aciclovir
- Penciclovir
- Idoxuridine
- Edoxudine
- Imiquimod/Resiquimod
- Podophyllotoxin
Docosanol
- Tromantadine
- Inosine
- Lysozyme
- Ibacitabine
|
|
Other
|
- Ingenol mebutate
- Metronidazole
|
|
|
|
|
noco (i/b/d/q/u/r/p/m/k/v/f)/cong/tumr (n/e/d), sysi/epon
|
proc, drug (D2/3/4/5/8/11)
|
|
|
|
Antibacterials: nucleic acid inhibitors (J01E, J01M)
|
|
Antifolates
(inhibits
purine metabolism,
thereby inhibiting
DNA and RNA synthesis) |
DHFR inhibitor |
- 2,4-Diaminopyrimidine
- Trimethoprim#
- Brodimoprim
- Tetroxoprim
- Iclaprim†
|
|
Sulfonamides
(DHPS inhibitor) |
Short-
acting |
- Sulfaisodimidine
- Sulfamethizole
- Sulfadimidine
- Sulfapyridine
- Sulfafurazole
- Sulfanilamide
- Sulfathiazole
- Sulfathiourea
|
|
Intermediate-
acting |
- Sulfamethoxazole
- Sulfadiazine#
- Sulfamoxole
|
|
Long-
acting |
- Sulfadimethoxine
- Sulfadoxine
- Sulfalene
- Sulfametomidine
- Sulfametoxydiazine
- Sulfamethoxypyridazine
- Sulfaperin
- Sulfamerazine
- Sulfaphenazole
- Sulfamazone
|
|
|
Other/ungrouped |
- sulfanilamide
- Sulfacetamide
- Sulfametrole
|
|
Combinations |
- Trimethoprim/sulfamethoxazole#
|
|
|
Topoisomerase
inhibitors/
quinolones/
(inhibits
DNA replication) |
1st g. |
- Cinoxacin‡
- Flumequine
- Nalidixic acid
- Oxolinic acid
- Pipemidic acid
- Piromidic acid
- Rosoxacin
|
|
Fluoro-
quinolones |
2nd g. |
- Ciprofloxacin#
- Enoxacin‡
- Fleroxacin‡
- Lomefloxacin
- Nadifloxacin
- Ofloxacin
- Norfloxacin
- Pefloxacin
- Rufloxacin
|
|
3rd g. |
- Balofloxacin
- Grepafloxacin‡
- Levofloxacin
- Pazufloxacin
- Sparfloxacin‡
- Temafloxacin‡
- Tosufloxacin
|
|
4th g. |
- Besifloxacin
- Clinafloxacin†
- Garenoxacin
- Gemifloxacin
- Moxifloxacin
- Gatifloxacin‡
- Sitafloxacin
- Trovafloxacin‡/Alatrofloxacin‡
- Prulifloxacin
|
|
Vet. |
- Danofloxacin
- Difloxacin
- Enrofloxacin
- Ibafloxacin
- Marbofloxacin
- Orbifloxacin
- Pradofloxacin
- Sarafloxacin
|
|
Related (DG) |
- Aminocoumarins: Novobiocin
|
|
|
|
Anaerobic DNA
inhibitors |
Nitro- imidazole derivatives |
- Metronidazole#
- Tinidazole
- Ornidazole
|
|
Nitrofuran derivatives |
- Nitrofurantoin#
- Furazolidone‡
- Nifurtoinol
|
|
|
RNA synthesis |
Rifamycins/
RNA polymerase |
- Rifampicin#
- Rifabutin
- Rifapentine
- Rifaximin
|
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
gr+f/gr+a (t)/gr-p (c)/gr-o
|
drug (J1p, w, n, m, vacc)
|
|
|
|
English Journal
- Relationship Between the Severity of Acne Vulgaris and Antimicrobial Resistance of Bacteria Isolated from Acne Lesions in a Hospital of Japan.
- Nakase K1, Nakaminami H, Takenaka Y, Hayashi N, Kawashima M, Noguchi N.Author information 1Department of Microbiology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432;AbstractPropionibacterium acnes and Staphylococcus epidermidis are normal skin inhabitants that are frequently isolated from lesions caused by acne, and these microorganisms are considered to contribute to the inflammation of acne. In the present study, we examined the antimicrobial susceptibilities and resistance mechanisms of P. acnes and S. epidermidis that were isolated from patients with acne vulgaris in a university hospital in Japan from 2009 to 2010. Additionally, we analysed the relationship between the antimicrobial resistance of P. acnes and the severity of acne vulgaris. Some P. acnes strains (18.8% (13/69)) were resistant to clindamycin. All strains had a mutation in the 23S rRNA gene, except for one strain that expressed erm(X) which encoded a 23S rRNA methylase. Tetracycline-resistant P. acnes were found in 4.3% (3/69) of the strains, and those resistances were caused by a mutation in the 16S rRNA gene. Furthermore, three strains with reduced susceptibility to nadifloxacin (MIC = 16 µg ml-1) were detected. When analysing the correlation between the antimicrobial resistance of P. acnes and S. epidermidis, more than 80% of the patients who carried clindamycin-resistant P. acnes also carried clindamycin-resistant S. epidermidis. However, no epidemic strain that exhibited antimicrobial resistance was detected in the P. acnes strains when analysed by pulsed-field gel electrophoresis. Therefore, our results suggest that the antimicrobial resistance of P. acne is closely related to antimicrobial therapy. Additionally, those P. acnes strains tended to be frequently found in severe acne patients rather than in mild acne patients. Consequently, the data support a relationship between using antimicrobial agents and the emergence of antimicrobial resistance.
- Journal of medical microbiology.J Med Microbiol.2014 Feb 12. doi: 10.1099/jmm.0.067611-0. [Epub ahead of print]
- Propionibacterium acnes and Staphylococcus epidermidis are normal skin inhabitants that are frequently isolated from lesions caused by acne, and these microorganisms are considered to contribute to the inflammation of acne. In the present study, we examined the antimicrobial susceptibilities and res
- PMID 24523159
- Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective.
- Wehler TC1, Graf C, Möhler M, Herzog J, Berger MR, Gockel I, Lang H, Theobald M, Galle PR, Schimanski CC.Author information 1Third Department of Internal Medicine, Johannes Gutenberg University of Mainz, Mainz, Germany, thomas.wehler@unimedizin-mainz.de.Erratum inJ Cancer Res Clin Oncol. 2013 Nov;139(11):1961-2. AbstractPURPOSE: Treatment with cetuximab is accompanied by the development of an acneiform follicular skin exanthema in more than 80 % of patients. Severe exanthema (grade III/IV) develops in about 9-19 % of patients with the necessity of cetuximab dose reduction or cessation.
- Journal of cancer research and clinical oncology.J Cancer Res Clin Oncol.2013 Oct;139(10):1667-72. doi: 10.1007/s00432-013-1483-4. Epub 2013 Aug 7.
- PURPOSE: Treatment with cetuximab is accompanied by the development of an acneiform follicular skin exanthema in more than 80 % of patients. Severe exanthema (grade III/IV) develops in about 9-19 % of patients with the necessity of cetuximab dose reduction or cessation.METHODS: The study presented w
- PMID 23918349
- Clinical and bacteriological evaluation of adapalene 0.1% gel plus nadifloxacin 1% cream versus adapalene 0.1% gel in patients with acne vulgaris.
- Takigawa M1, Tokura Y, Shimada S, Furukawa F, Noguchi N, Ito T; Acne Study Group.Author information 1Hamamatsu University School of Medicine, Tokyo, Japan. toriimd@shahochu.jpAbstractThis multicenter, randomized parallel group study investigated the efficacy and tolerability of adapalene 0.1% gel plus nadifloxacin 1% cream (combination therapy) compared with adapalene gel (monotherapy) during 12-week treatment of acne vulgaris. A total of 184 Japanese patients aged above 12 years with moderate to severe acne as indicated by the Japanese severity grading criteria were randomized to combination therapy (n = 84) and monotherapy (n = 100) groups, both having comparable demographic and baseline characteristics. Adapalene was applied only to inflammatory acne lesions in order to minimize skin irritation and ensure the treatment results. Efficacy and safety evaluations, treatment compliance and satisfaction with drug application were periodically monitored. The combination therapy provided a significantly greater efficacy than adapalene in decrement of inflammatory papulopustular lesions at 4 weeks and thereafter (P = 0.0056). The overall judgment of the therapeutic efficacy by the physician at the end of study revealed a significant difference (P = 0.02496) between the groups in favor of combination therapy. Dryness was reported in a greater proportion of patients undergoing monotherapy than combination therapy at weeks 2 and 4 (P = 0.04652). The patient self-assessment in satisfaction with the drug application at the end of study revealed a significant difference (P = 0.00268) between the groups in favor of combination therapy. Among 76 strains of Propionibacterium acnes isolated from 87 patients, no strain was resistant to nadifloxacin. Thus, the simultaneous use of adapalene and nadifloxacin may provide an additive and complementary effect, resulting in clinical superiority and greater patient adherence compared to adapalene monotherapy.
- The Journal of dermatology.J Dermatol.2013 Aug;40(8):620-5. doi: 10.1111/1346-8138.12189. Epub 2013 Jun 3.
- This multicenter, randomized parallel group study investigated the efficacy and tolerability of adapalene 0.1% gel plus nadifloxacin 1% cream (combination therapy) compared with adapalene gel (monotherapy) during 12-week treatment of acne vulgaris. A total of 184 Japanese patients aged above 12 yea
- PMID 23724808
Japanese Journal
- 症例 ナジフロキサシンクリーム外用後に発症した接触皮膚炎症候群
- 大谷 道輝,山岡 由紗,松元 美香,並木 路広,山村 喜一,江藤 隆史
- 薬剤学 = The archives of practical pharmacy 69(6), 470-476, 2009-11-01
- NAID 10025720959
Related Links
- The Basics Type of Treatment: Rx Medicatio... ... Topical Nadifloxacin tends to have minimal side effects, most of which are mild. Allergic reactions are the most common problem associated with this medication.
- ナジフロキサシン(Nadifloxacin)の検索ならお薬検索QLife(キューライフ)。お医者さんが処方する処方薬と、薬局で買える市販薬(OTC)、の効果と副作用、写真、添付文書、保管方法等を掲載。商品名だけでなく一般名や剤形、色などからも ...
Related Pictures
★リンクテーブル★
[★]
- 英
- nadifloxacin
- 商
- アクアチム、ナジフロ、ナジロキサン